Could a Two-Drug combo outsmart advanced cervical cancer?

NCT ID NCT07652983

Not yet recruiting Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a combination of two drugs, iparomlimab and tuvonralimab (called QL1706), works for people with recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. Researchers will compare outcomes of those receiving QL1706 to those getting standard chemotherapy in routine care. They will also explore whether adding another drug, bevacizumab, improves results and which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab and tuvonralimab (QL1706)
What this could lead to: If successful, this could show that QL1706-based therapy offers a better treatment option for people with advanced cervical cancer who have not responded to standard chemotherapy.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. The therapy may not prove more effective than existing options and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Recurrence Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC CERVICAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.